文献速递心脑血管急症重症综合管理与镇静镇痛

弥漫性血管造影阴性蛛网膜下腔出血与中间型临床病程相关

Diffuse Angiogram-Negative Subarachnoid Hemorrhage is Associated with an Intermediate Clinical Course.
PubMed 文献 · Neurocrit Care · 2021-12-21
一句话结论弥漫性蛛网膜下腔出血预后介于环中脑与动脉瘤性SAH之间,需高 acuity 观察。

这项回顾性队列研究纳入2012年1月1日至2017年12月31日一家三级转诊中心所有非创伤性蛛网膜下腔出血(SAH)患者,按出血模式分为环中脑SAH(86例)、弥漫性SAH(174例)和动脉瘤性SAH(998例)。弥漫性SAH的危重症并发症(低血压和休克3.5% vs. 16.1% vs. 38.4%,气管插管0% vs. 26.4% vs. 48.8%)和脑脊液分流需求(9.3% vs. 54.6% vs. 76.3%)介于环中脑SAH与动脉瘤性SAH之间。出院时非家庭出院率23.0%、功能状态差26.4%,出院后1-6个月良好功能结局92.3% vs. 78.6% vs. 47.3%。作者认为弥漫性SAH具有中间型预后,强调急性期需警惕并持续高 acuity 观察。

要点

  • 弥漫性SAH患者气管插管率26.4%,显著高于环中脑SAH的0%,低于动脉瘤性SAH的48.8%(p < 0.01)。
  • 弥漫性SAH患者低血压和休克发生率16.1%,介于环中脑SAH的3.5%与动脉瘤性SAH的38.4%之间(p < 0.01)。
  • 弥漫性SAH脑脊液分流需求54.6%,高于环中脑SAH的9.3%,低于动脉瘤性SAH的76.3%(p < 0.001)。
  • 弥漫性SAH出院时非家庭出院率23.0%、功能状态差26.4%,显著高于环中脑SAH、低于动脉瘤性SAH。
  • 出院后1-6个月良好功能结局:环中脑SAH 92.3% vs. 弥漫性SAH 78.6% vs. 动脉瘤性SAH 47.3%(p < 0.016)。

适用人群与场景

  • 2012年1月1日至2017年12月31日一家三级转诊中心收治的所有非创伤性蛛网膜下腔出血患者。
  • 按影像学出血模式分为环中脑SAH、弥漫性SAH和动脉瘤性SAH三组。

研究设计与关键结果

  • 回顾性队列研究,纳入环中脑SAH 86例、弥漫性SAH 174例、动脉瘤性SAH 998例。
  • 动脉瘤性SAH患者显著更可能为女性、白种人和主动吸烟者;弥漫性SAH与环中脑SAH患者之间无显著差异。
  • 低血压和休克发生率:环中脑SAH 3.5% vs. 弥漫性SAH 16.1% vs. 动脉瘤性SAH 38.4%(p < 0.01)。
  • 气管插管率:环中脑SAH 0% vs. 弥漫性SAH 26.4% vs. 动脉瘤性SAH 48.8%(p < 0.01)。
  • 脑脊液分流需求:环中脑SAH 9.3% vs. 弥漫性SAH 54.6% vs. 动脉瘤性SAH 76.3%(p < 0.001)。
  • 长期支持治疗(气管切开和胃造瘘管)及住院时间呈现相似趋势。
  • 血管痉挛和迟发性脑缺血在环中脑SAH与弥漫性SAH之间相当,但均显著低于动脉瘤性SAH。
  • 弥漫性SAH出院时非家庭出院率23.0%、功能状态差26.4%,显著高于环中脑SAH、低于动脉瘤性SAH。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,弥漫性SAH预后介于环中脑SAH与动脉瘤性SAH之间,比环中脑SAH更差但不如动脉瘤性SAH严重。
  • 作者认为,弥漫性SAH相关显著病残率强调急性期护理需保持警惕。
  • 作者认为,这些患者可能受益于持续高 acuity 观察和潜在支持,以规避显著病残和神经功能损害风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The cerebral angiography result is negative for an underlying vascular lesion in 15-20% of patients with nontraumatic subarachnoid hemorrhage (SAH). Patients with angiogram-negative SAH include those with perimesencephalic SAH and diffuse SAH. Consensus suggests that perimesencephalic SAH confers a more favorable prognosis than diffuse SAH. Limited data exist to contextualize the clinical course and prognosis of diffuse SAH in relation to aneurysmal SAH in terms of critical care complications, neurologic complications, and functional outcomes. Here we compare the clinical course and functional outcomes of patients with perimesencephalic SAH, diffuse SAH, and aneurysmal SAH to better characterize the prognostic implications of each SAH subtype.

METHODS: We conducted a retrospective cohort study that included all patients with nontraumatic SAH admitted to a tertiary care referral center between January 1, 2012, and December 31, 2017. Bleed patterns were radiographically adjudicated, and patients were assigned to three groups: perimesencephalic SAH, diffuse SAH, and aneurysmal SAH. Patient demographics, complications, and clinical outcomes were reported and compared.

RESULTS: Eighty-six patients with perimesencephalic SAH, 174 with diffuse SAH, and 998 with aneurysmal SAH presented during the study period. Patients with aneurysmal SAH were significantly more likely to be female, White, and active smokers. There were no significant differences between patients with diffuse SAH and perimesencephalic SAH patterns. Critical care complications were compared across all three groups, with significant between-group differences in hypotension and shock (3.5% vs. 16.1% vs. 38.4% for perimesencephalic SAH vs. diffuse SAH vs. aneurysmal SAH, respectively; p < 0.01) and endotracheal intubation (0% vs. 26.4% vs. 48.8% for perimesencephalic SAH vs. diffuse SAH vs. aneurysmal SAH, respectively; p < 0.01). Similar trends were noted with long-term supportive care with tracheostomy and gastrostomy tubes and length of stay. Cerebrospinal fluid diversion was increasingly required across bleed types (9.3% vs. 54.6% vs. 76.3% for perimesencephalic SAH vs. diffuse SAH vs. aneurysmal SAH, respectively, p < 0.001). Vasospasm and delayed cerebral ischemia were comparable between perimesencephalic SAH and diffuse SAH but significantly lower than aneurysmal SAH. Patients with diffuse SAH had intermediate functional outcomes, with significant rates of nonhome discharge (23.0%) and poor functional status on discharge (26.4%), significantly higher than patients with perimesencephalic SAH and lower than patients with aneurysmal SAH. Diffuse SAH similarly conferred an intermediate rate of good functional outcomes at 1-6 months post discharge (92.3% vs. 78.6% vs. 47.3% for perimesencephalic SAH vs. diffuse SAH vs. aneurysmal SAH, respectively; p < 0.016).

CONCLUSIONS: We confirm the consensus data that perimesencephalic SAH is associated with a more benign clinical course but demonstrate that diffuse SAH confers an intermediate prognosis, more malignant than perimesencephalic SAH but not as morbid as aneurysmal SAH. These results highlight the significant morbidity associated with diffuse SAH and emphasize need for vigilance in the acute care of these patients. These patients will likely benefit from continued high-acuity observation and potential support to avert significant risk of morbidity and neurologic compromise.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Akbik F, Pimentel-Farias C, Press DA, et al. Diffuse Angiogram-Negative Subarachnoid Hemorrhage is Associated with an Intermediate Clinical Course. Neurocrit Care. 2021. PMID: 34932193. doi:10.1007/s12028-021-01413-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。